Novel Type 2 Diabetes Mellitus Preventive Therapies

Completed · Phase 1

Conditions studied: Diabetes

In brief

Over the past two decades, type 2 diabetes mellitus (T2DM) has emerged from relative obscurity to become one of the most serious complications of obesity in Hispanic obese populations, especially among those with a family history of T2DM. Few therapies have demonstrated long term efficacy in combating obesity and risk of T2DM in youth. Given the emerging evidence that glutamine and leucine (building blocks of protein) may affect energy partition and thus diabetes risk, and that the relationship of glutamine and diabetic risk has been further evaluated in one adult observational cohort study but data on leucine are lacking, we plan to conduct a clinical trial to determine the efficacy of glutamine to reduce insulin resistance, a diabetes risk factor. The primary specific aim of the research plan is to conduct a randomized, double-blind, placebo controlled, clinical trial to test the efficacy of 6 months supplements of glutamine in reducing biomarkers for insulin resistance and weight gain among 56 obese Hispanic adolescents age 12-19 years with a BMI at or above the 95th percentile and a family history of T2DM. At the end of the grant period, we will have obtained preliminary data to plan pivotal clinical trials of glutamine coupled with or without lifestyle changes.

Key facts

Study ID

NCT02351323

Run by

Boston Medical Center

People needed

12

Starts

2010-05-01

Expected to finish

2014-08-01

Last updated by the study team

2015-01-30

Who can join

Age: 12 and older, up to 19. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• BMI (k/m2) >= 95th percentile;
• Weight 150 - 400 pounds;
• Language: English or Spanish (The PI speaks both English and Spanish fluently).

You may not qualify if…

• History of T2DM;
• Prior or current drug treatmeant that would effect diabetes risk
• Use of prescription strength glucocorticoids within three months before screening,
• History of syndrome or medical disorder associated with significant obesity;
• Serum creatinine >1.2 mg/dL;
• Alanine transaminase (ALT) or Aspartate aminotransferase (AST) >90 international units (IU)/L (= 3 X normal limits);
• Total bilirubin >2.5 time the upper limit of normal;
• History of moderate to extreme physical activity, past or current pregnancy;
• 9 .Use of illegal/illicit drugs;
• Unable to comply with the protocol;
• Any other serious disease determined by the clinician as potential study risk for the patient.
• Have kidney or liver disorders, or conditions resulting in ammonia accumulation
• Take Lactulose
• Are allergic to monosodium glutamate (MSG), glutamine, or Crystal Light
• Have manic episodes (mental illness)
• Take medications to prevent seizures
• Take any glutamine, supplement with glutamine, hypoglycemiants, anticonvulsivant, ADHD medications, antilipidemiants, or thyroid hormone
• Participation in a weight loss program or use of weight loss medications within six months of screening that has resulted in 5% or more weight loss

Where it is running

• Boston Medical Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.